^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Cancer

    Related cancers:
    17h
    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca (clinicaltrials.gov)
    P1/2, N=83, Recruiting, Virginia Commonwealth University | Trial completion date: May 2027 --> Jan 2031 | Trial primary completion date: May 2026 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    RAS mutation
    |
    Nerlynx (neratinib)
    22h
    Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Nanfang Hospital, Southern Medical University
    New trial
    22h
    HRCC: The Hugo RAS Colorectal Collaborative (clinicaltrials.gov)
    P=N/A, N=2000, Not yet recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New trial
    22h
    NIVO402025: Phase II Open-lable Single-center Clinical Study of the Efficacy and Safety of Low-dose Immunotherapy in the Treatment of Patients With Metastatic and Locally Advanced Colorectal and Gastric Cancers With Microsatellite Unstable Phenotype (MSI)/Deficiency of Mismatch Repair System (dMMR) (clinicaltrials.gov)
    P2, N=128, Enrolling by invitation, Blokhin's Russian Cancer Research Center
    New P2 trial • Mismatch repair • dMMR
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil
    22h
    A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Kumquat Biosciences Inc.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12 • KRAS G12S
    23h
    A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=190, Recruiting, Taizhou Hanzhong biomedical co. LTD | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment open • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Puyouheng (pucotenlimab)
    23h
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=300, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=117 --> 300
    Enrollment open • Enrollment change
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    1d
    PK equivalence: A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=387, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1d
    Supportive Oncology Care At Home RCT (clinicaltrials.gov)
    P=N/A, N=300, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    ETAP: Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer (clinicaltrials.gov)
    P3, N=226, Completed, Institut Paoli-Calmettes | Recruiting --> Completed | Trial completion date: Jan 2024 --> Sep 2025 | Trial primary completion date: Jan 2021 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    1d
    Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD) (clinicaltrials.gov)
    P=N/A, N=6, Not yet recruiting, Vanderbilt University Medical Center | Trial completion date: Jun 2026 --> Jan 2027 | Initiation date: Feb 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date • First-in-human
    1d
    Later-generation epigenetic aging clocks outperform first-generation models in predicting survival in TCGA breast cancer. (PubMed, Clin Epigenetics)
    Second-generation clocks demonstrated stronger prognostic signal than first-generation models in unadjusted analyses. Among them, GrimAge1 retained independent prognostic value beyond established clinicopathologic factors in breast cancer, supporting further external validation with richer covariates to refine clinical utility.
    Journal
    |
    BRCA (Breast cancer early onset)